{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,29]],"date-time":"2026-08-29T04:51:41Z","timestamp":1787979101137,"version":"build-2784847793"},"reference-count":114,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2023,7,1]],"date-time":"2023-07-01T00:00:00Z","timestamp":1688169600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,7,1]],"date-time":"2023-07-01T00:00:00Z","timestamp":1688169600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,6,9]],"date-time":"2023-06-09T00:00:00Z","timestamp":1686268800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.es","elsevier.es","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Actas Dermo-Sifiliogr\u00e1ficas"],"published-print":{"date-parts":[[2023,7]]},"DOI":"10.1016\/j.ad.2023.06.007","type":"journal-article","created":{"date-parts":[[2023,6,10]],"date-time":"2023-06-10T08:36:11Z","timestamp":1686386171000},"page":"T613-T626","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["[Translated article] Pruritus in Dermatology: Part 2\u2014Diseases and Their Treatment"],"prefix":"10.1016","volume":"114","author":[{"given":"F.J.","family":"Navarro-Trivi\u00f1o","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ad.2023.06.007_bib0575","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1111\/j.1365-2133.2008.08941.x","article-title":"Itch characteristics in atopic dermatitis: results of a web-based questionnaire","volume":"160","author":"Dawn","year":"2009","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.ad.2023.06.007_bib0580","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1007\/s12016-015-8488-5","article-title":"Mediators of chronic pruritus in atopic dermatitis: getting the itch out?","volume":"51","author":"Mollanazar","year":"2016","journal-title":"Clin Rev Allergy Immunol"},{"key":"10.1016\/j.ad.2023.06.007_bib0585","doi-asserted-by":"crossref","DOI":"10.1016\/j.cell.2017.08.006","article-title":"Sensory neurons co-opt classical immune signaling pathways to mediate chronic itch","volume":"171","author":"Oetjen","year":"2017","journal-title":"Cell"},{"key":"10.1016\/j.ad.2023.06.007_bib0590","doi-asserted-by":"crossref","first-page":"1524","DOI":"10.1016\/j.jid.2020.01.012","article-title":"PAR2 mediates itch via TRPV3 signaling in keratinocytes","volume":"140","author":"Zhao","year":"2020","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.ad.2023.06.007_bib0595","doi-asserted-by":"crossref","DOI":"10.1016\/j.jaci.2020.09.028","article-title":"Novel insights into the TRPV3-mediated itch in atopic dermatitis","volume":"147","author":"Larkin","year":"2021","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.ad.2023.06.007_bib0600","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1016\/j.jdermsci.2017.07.010","article-title":"Antimicrobial peptides human LL-37 and \u03b2-defensin-3 modulate the expression of nerve elongation factors in human epidermal keratinocytes","volume":"88","author":"Umehara","year":"2017","journal-title":"J Dermatol Sci"},{"key":"10.1016\/j.ad.2023.06.007_bib0605","doi-asserted-by":"crossref","first-page":"1072","DOI":"10.1111\/j.1365-2133.2009.09308.x","article-title":"Distinct patterns of brain activity evoked by histamine-induced itch reveal an association with itch intensity and disease severity in atopic dermatitis","volume":"161","author":"Ishiuji","year":"2009","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.ad.2023.06.007_bib0610","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1007\/s00105-022-05011-7","article-title":"Pruritus in atopic dermatitis-comparative evaluation of novel treatment approaches [Article in German]","volume":"73","author":"M\u00fcller","year":"2022","journal-title":"Dermatologie (Heidelb)"},{"key":"10.1016\/j.ad.2023.06.007_bib0615","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1007\/s40257-022-00685-0","article-title":"Dupilumab provides acceptable safety and sustained efficacy for up to 4 years in an open-label study of adults with moderate-to-severe atopic dermatitis","volume":"23","author":"Beck","year":"2022","journal-title":"Am J Clin Dermatol"},{"key":"10.1016\/j.ad.2023.06.007_bib0620","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1001\/jamadermatol.2020.0079","article-title":"Efficacy and safety of lebrikizumab, a high-affinity interleukin 13 inhibitor, in adults with moderate to severe atopic dermatitis: a phase 2b randomized clinical trial","volume":"156","author":"Guttman-Yassky","year":"2020","journal-title":"JAMA Dermatol"},{"key":"10.1016\/j.ad.2023.06.007_bib0625","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1007\/978-94-017-7537-3_2","article-title":"Allergic contact dermatitis: a model of inflammatory itch and pain in human and mouse","volume":"904","author":"LaMotte","year":"2016","journal-title":"Adv Exp Med Biol"},{"key":"10.1016\/j.ad.2023.06.007_bib0630","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1016\/j.jaci.2014.03.009","article-title":"Molecular profiling of contact dermatitis skin identifies allergen-dependent differences in immune response","volume":"134","author":"Dhingra","year":"2014","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.ad.2023.06.007_bib0635","doi-asserted-by":"crossref","first-page":"236","DOI":"10.2340\/00015555-0650","article-title":"Drug-induced pruritus: a review","volume":"89","author":"Reich","year":"2009","journal-title":"Acta Derm Venereol"},{"key":"10.1016\/j.ad.2023.06.007_bib0640","first-page":"31","article-title":"Progress and challenges in the understanding of chronic urticaria","volume":"3","author":"Ferrer","year":"2007","journal-title":"Allergy Asthma Clin Immunol"},{"key":"10.1016\/j.ad.2023.06.007_bib0645","doi-asserted-by":"crossref","first-page":"1265","DOI":"10.1016\/j.jaci.2022.10.014","article-title":"An update on anaphylaxis and urticaria","volume":"150","author":"Worm","year":"2022","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.ad.2023.06.007_bib0650","doi-asserted-by":"crossref","first-page":"2807","DOI":"10.3390\/jcm11102807","article-title":"Bruton's kinase inhibitors for the treatment of immunological diseases: current status and perspectives","volume":"11","author":"Robak","year":"2022","journal-title":"J Clin Med"},{"key":"10.1016\/j.ad.2023.06.007_bib0655","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1016\/j.anai.2019.08.014","article-title":"New treatments for chronic urticaria","volume":"124","author":"Kolkhir","year":"2020","journal-title":"Ann Allergy Asthma Immunol"},{"key":"10.1016\/j.ad.2023.06.007_bib0660","doi-asserted-by":"crossref","DOI":"10.1016\/j.jaip.2018.11.018","article-title":"Dupilumab as a novel therapy for difficult to treat chronic spontaneous urticaria","volume":"7","author":"Lee","year":"2019","journal-title":"J Allergy Clin Immunol Pract"},{"key":"10.1016\/j.ad.2023.06.007_bib0665","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1111\/ddg.13481","article-title":"Benefit of mepolizumab treatment in a patient with chronic spontaneous urticaria","volume":"16","author":"Magerl","year":"2018","journal-title":"J Dtsch Dermatol Ges"},{"key":"10.1016\/j.ad.2023.06.007_bib0670","doi-asserted-by":"crossref","first-page":"adv00796","DOI":"10.2340\/actadv.v102.4367","article-title":"Lichen simplex chronicus itch: an update","volume":"102","author":"Ju","year":"2022","journal-title":"Acta Derm Venereol"},{"key":"10.1016\/j.ad.2023.06.007_bib0675","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1046\/j.1365-2133.2000.03829.x","article-title":"The prevalence and clinical characteristics of pruritus among patients with extensive psoriasis","volume":"143","author":"Yosipovitch","year":"2000","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.ad.2023.06.007_bib0680","doi-asserted-by":"crossref","first-page":"8406","DOI":"10.3390\/ijms21218406","article-title":"Molecular and cellular mechanisms of itch in psoriasis","volume":"21","author":"Komiya","year":"2020","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.ad.2023.06.007_bib0685","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.bbi.2014.03.004","article-title":"Participation of interleukin 17A in neuroimmune interactions","volume":"41","author":"Moynes","year":"2014","journal-title":"Brain Behav Immun"},{"key":"10.1016\/j.ad.2023.06.007_bib0690","doi-asserted-by":"crossref","first-page":"98","DOI":"10.2340\/00015555-2801","article-title":"Long-term impact of ixekizumab on psoriasis itch severity: results from a phase III clinical trial and long-term extension","volume":"98","author":"Kimball","year":"2018","journal-title":"Acta Derm Venereol"},{"key":"10.1016\/j.ad.2023.06.007_bib0695","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1056\/NEJMoa2102383","article-title":"Bimekizumab versus secukinumab in plaque psoriasis","volume":"385","author":"Reich","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ad.2023.06.007_bib0700","doi-asserted-by":"crossref","first-page":"1652","DOI":"10.1111\/jdv.15075","article-title":"Inflammatory cytokines and peripheral mediators in the pathophysiology of pruritus in cutaneous T-cell lymphoma","volume":"32","author":"Lewis","year":"2018","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.ad.2023.06.007_bib0705","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1016\/j.jaad.2011.12.021","article-title":"Pruritus in cutaneous T-cell lymphoma: a review","volume":"67","author":"Ahern","year":"2012","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.ad.2023.06.007_bib0710","doi-asserted-by":"crossref","first-page":"372","DOI":"10.7326\/0003-4819-109-5-372","article-title":"Histopathologic staging at initial diagnosis of mycosis fungoides and the S\u00e9zary syndrome. Definition of three distinctive prognostic groups","volume":"109","author":"Sausville","year":"1988","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.ad.2023.06.007_bib0715","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1001\/archderm.1993.01680250045005","article-title":"Peripheral blood mononuclear cells in patients with nonleukemic cutaneous T-cell lymphoma. Reduced proliferation and preferential secretion of a T helper-2-like cytokine pattern on stimulation","volume":"129","author":"Dummer","year":"1993","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.ad.2023.06.007_bib0720","doi-asserted-by":"crossref","first-page":"e13880","DOI":"10.1111\/dth.13880","article-title":"Progression of mycosis fungoides after treatment with dupilumab: a case report","volume":"33","author":"Miyashiro","year":"2020","journal-title":"Dermatol Ther"},{"key":"10.1016\/j.ad.2023.06.007_bib0725","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1016\/j.ad.2013.07.007","article-title":"Aprepitant in the treatment of refractory pruritus secondary to cutaneous T-cell lymphoma","volume":"105","author":"Borja-Consigliere","year":"2014","journal-title":"Actas Dermosifiliogr"},{"key":"10.1016\/j.ad.2023.06.007_bib0730","doi-asserted-by":"crossref","DOI":"10.2340\/00015555-3923","article-title":"Pruritus in keloid scars: mechanisms and treatments","volume":"101","author":"Hawash","year":"2021","journal-title":"Acta Derm Venereol"},{"key":"10.1016\/j.ad.2023.06.007_bib0735","doi-asserted-by":"crossref","first-page":"53","DOI":"10.3390\/dermatopathology7030009","article-title":"Histological changes related to symptomatic improvement of spontaneous keloids treated with a low-dosage regimen of UVA-1 phototherapy","volume":"7","author":"Cuenca-Barrales","year":"2020","journal-title":"Dermatopathology (Basel)"},{"key":"10.1016\/j.ad.2023.06.007_bib0740","doi-asserted-by":"crossref","first-page":"e161","DOI":"10.1111\/jdv.16097","article-title":"Keloid lesions show increased IL-4\/IL-13 signaling and respond to Th2-targeting dupilumab therapy","volume":"34","author":"Diaz","year":"2020","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.ad.2023.06.007_bib0745","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1111\/j.1365-2230.2004.01510.x","article-title":"Pruritus in adult dermatomyositis","volume":"29","author":"Shirani","year":"2004","journal-title":"Clin Exp Dermatol"},{"key":"10.1016\/j.ad.2023.06.007_bib0750","doi-asserted-by":"crossref","first-page":"2982","DOI":"10.1111\/all.14791","article-title":"Interleukin-31: the \u201citchy\u201d cytokine in inflammation and therapy","volume":"76","author":"Datsi","year":"2021","journal-title":"Allergy"},{"key":"10.1016\/j.ad.2023.06.007_bib0755","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1111\/bjd.14678","article-title":"Small-fibre neuropathy in a patient with dermatomyositis and severe scalp pruritus","volume":"176","author":"Hurliman","year":"2017","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.ad.2023.06.007_bib0760","doi-asserted-by":"crossref","first-page":"1392","DOI":"10.1111\/bjd.14998","article-title":"Itch and systemic sclerosis: frequency, clinical characteristics and consequences","volume":"176","author":"Th\u00e9r\u00e9n\u00e9","year":"2017","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.ad.2023.06.007_bib0765","doi-asserted-by":"crossref","first-page":"735","DOI":"10.2340\/00015555-2980","article-title":"Clinical characteristics of pruritus in systemic sclerosis vary according to the autoimmune subtype","volume":"98","author":"Gourier","year":"2018","journal-title":"Acta Derm Venereol"},{"key":"10.1016\/j.ad.2023.06.007_bib0770","doi-asserted-by":"crossref","first-page":"1385","DOI":"10.1177\/09612033211016098","article-title":"Clinical characteristics of itch in cutaneous lupus erythematosus: a prospective, multicenter, multinational, cross-sectional study","volume":"30","author":"Samotij","year":"2021","journal-title":"Lupus"},{"key":"10.1016\/j.ad.2023.06.007_bib0775","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1186\/s42358-020-00133-9","article-title":"Small fiber neuropathy and related factors in patients with systemic lupus erythematosus; the results of cutaneous silent period and skin biopsy","volume":"60","author":"Tekatas","year":"2020","journal-title":"Adv Rheumatol"},{"key":"10.1016\/j.ad.2023.06.007_bib0780","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1007\/s00393-013-1274-y","article-title":"Serum levels of cytokines in systemic lupus erythematosus: association study in a Chinese population","volume":"73","author":"Zhang","year":"2014","journal-title":"Z Rheumatol"},{"key":"10.1016\/j.ad.2023.06.007_bib0785","doi-asserted-by":"crossref","first-page":"2525","DOI":"10.1007\/s11136-018-1897-1","article-title":"Association between quality of life and clinical characteristics in patients with morphea","volume":"27","author":"Bali","year":"2018","journal-title":"Qual Life Res"},{"key":"10.1016\/j.ad.2023.06.007_bib0790","first-page":"55","article-title":"Sj\u00f6gren's syndrome: a retrospective review of the cutaneous features of 93 patients by the Italian Group of Immunodermatology","volume":"22","author":"Bernacchi","year":"2004","journal-title":"Clin Exp Rheumatol"},{"key":"10.1016\/j.ad.2023.06.007_bib0795","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1002\/mus.26824","article-title":"Small fiber neuropathy in Sj\u00f6gren syndrome: comparison with other small fiber neuropathies","volume":"61","author":"Descamps","year":"2020","journal-title":"Muscle Nerve"},{"key":"10.1016\/j.ad.2023.06.007_bib0800","doi-asserted-by":"crossref","first-page":"1772","DOI":"10.3390\/diagnostics12071772","article-title":"Autoimmune connective tissue diseases-related pruritus: proper diagnosis and possible mechanisms","volume":"12","author":"Wong","year":"2022","journal-title":"Diagnostics (Basel)"},{"key":"10.1016\/j.ad.2023.06.007_bib0805","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.nefroe.2022.02.004","article-title":"Pruritus in dialysis patients. Review and new perspectives","volume":"42","author":"Santos-Alonso","year":"2022","journal-title":"Nefrologia (Engl Ed)"},{"key":"10.1016\/j.ad.2023.06.007_bib0810","doi-asserted-by":"crossref","first-page":"1626","DOI":"10.1038\/sj.ki.5000251","article-title":"Etiology and prognostic significance of severe uremic pruritus in chronic hemodialysis patients","volume":"69","author":"Narita","year":"2006","journal-title":"Kidney Int"},{"key":"10.1016\/j.ad.2023.06.007_bib0815","doi-asserted-by":"crossref","first-page":"1387","DOI":"10.1016\/j.ekir.2020.04.027","article-title":"CKD-associated pruritus: new insights into diagnosis pathogenesis, and management","volume":"5","author":"Verduzco","year":"2020","journal-title":"Kidney Int Rep"},{"key":"10.1016\/j.ad.2023.06.007_bib0820","doi-asserted-by":"crossref","first-page":"1183","DOI":"10.1093\/ndt\/gfp592","article-title":"Free p-cresylsulphate is a predictor of mortality in patients at different stages of chronic kidney disease","volume":"25","author":"Liabeuf","year":"2010","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.ad.2023.06.007_bib0825","first-page":"18","volume":"64","year":"2022","journal-title":"Med Lett Drugs Ther"},{"key":"10.1016\/j.ad.2023.06.007_bib0830","doi-asserted-by":"crossref","first-page":"e23229","DOI":"10.1097\/MD.0000000000023229","article-title":"Effectiveness of montelukast for uremic pruritus in hemodialysis patients: a protocol for systematic review and meta-analysis","volume":"99","author":"Gao","year":"2020","journal-title":"Medicine (Baltimore)"},{"key":"10.1016\/j.ad.2023.06.007_bib0835","first-page":"CD011393","article-title":"Interventions for itch in people with advanced chronic kidney disease","volume":"12","author":"Hercz","year":"2020","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.ad.2023.06.007_bib0840","doi-asserted-by":"crossref","first-page":"639674","DOI":"10.3389\/fmed.2021.639674","article-title":"Cholestasis-associated pruritus and its pruritogens","volume":"8","author":"Langedijk","year":"2021","journal-title":"Front Med (Lausanne)"},{"key":"10.1016\/j.ad.2023.06.007_bib0845","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.3748\/wjg.v12.i7.1125","article-title":"Effect of oral naltrexone on pruritus in cholestatic patients","volume":"12","author":"Mansour-Ghanaei","year":"2006","journal-title":"World J Gastroenterol"},{"key":"10.1016\/j.ad.2023.06.007_bib0850","doi-asserted-by":"crossref","first-page":"e48431","DOI":"10.7554\/eLife.48431","article-title":"MRGPRX4 is a bile acid receptor for human cholestatic itch","volume":"8","author":"Yu","year":"2019","journal-title":"Elife"},{"key":"10.1016\/j.ad.2023.06.007_bib0855","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1159\/000360518","article-title":"Advances in pathogenesis and management of pruritus in cholestasis","volume":"32","author":"Kremer","year":"2014","journal-title":"Dig Dis"},{"key":"10.1016\/j.ad.2023.06.007_bib0860","doi-asserted-by":"crossref","first-page":"4238139","DOI":"10.1155\/2017\/4238139","article-title":"Prevalence and relevance of pruritus in pregnancy","volume":"2017","author":"Szcz\u0119ch","year":"2017","journal-title":"Biomed Res Int"},{"key":"10.1016\/j.ad.2023.06.007_bib0865","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1007\/s40257-021-00668-7","article-title":"Pruritus in pregnancy","volume":"23","author":"Stefaniak","year":"2022","journal-title":"Am J Clin Dermatol"},{"key":"10.1016\/j.ad.2023.06.007_bib0870","doi-asserted-by":"crossref","first-page":"261","DOI":"10.2340\/00015555-1959","article-title":"Paraneoplastic itch: an expert position statement from the Special Interest Group (SIG) of the International Forum on the Study of Itch (IFSI)","volume":"95","author":"Weisshaar","year":"2015","journal-title":"Acta Derm Venereol"},{"key":"10.1016\/j.ad.2023.06.007_bib0875","doi-asserted-by":"crossref","first-page":"496","DOI":"10.2340\/00015555-2906","article-title":"Aquagenic pruritus in polycythemia vera: clinical characteristics","volume":"98","author":"Lelonek","year":"2018","journal-title":"Acta Derm Venereol"},{"key":"10.1016\/j.ad.2023.06.007_bib0880","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1684\/ejd.2010.1196","article-title":"Increased expression of mRNAs for IL-4, IL-17, IL-22 and IL-31 in skin lesions of subacute and chronic forms of pr\u00farigo","volume":"21","author":"Park","year":"2011","journal-title":"Eur J Dermatol"},{"key":"10.1016\/j.ad.2023.06.007_bib0885","doi-asserted-by":"crossref","first-page":"12390","DOI":"10.3390\/ijms232012390","article-title":"Chronic nodular prurigo: an update on the pathogenesis and treatment","volume":"23","author":"Wong","year":"2022","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.ad.2023.06.007_bib0890","doi-asserted-by":"crossref","first-page":"e15642","DOI":"10.1111\/dth.15642","article-title":"Successful treatment of refractory prurigo nodularis with baricitinib","volume":"35","author":"Yin","year":"2022","journal-title":"Dermatol Ther"},{"key":"10.1016\/j.ad.2023.06.007_bib0895","doi-asserted-by":"crossref","first-page":"2039","DOI":"10.1007\/s13555-022-00782-2","article-title":"Prurigo nodularis: a review of IL-31RA blockade and other potential treatments","volume":"12","author":"Bewley","year":"2022","journal-title":"Dermatol Ther (Heidelb)"},{"key":"10.1016\/j.ad.2023.06.007_bib0900","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1016\/j.ad.2021.12.014","article-title":"Nemolizumab: an innovative biologic treatment to control interleukin 31, a key mediator in atopic dermatitis and prurigo nodularis","volume":"113","author":"Serra-Baldrich","year":"2022","journal-title":"Actas Dermosifiliogr"},{"key":"10.1016\/j.ad.2023.06.007_bib0905","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1056\/NEJMoa1917006","article-title":"Trial of nemolizumab and topical agents for atopic dermatitis with pruritus","volume":"383","author":"Kabashima","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ad.2023.06.007_bib0910","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1056\/NEJMoa1908316","article-title":"Trial of nemolizumab in moderate-to-severe prurigo nodularis","volume":"382","author":"St\u00e4nder","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ad.2023.06.007_bib0915","doi-asserted-by":"crossref","first-page":"adv00197","DOI":"10.2340\/00015555-3505","article-title":"Induction of monocyte chemoattractant protein 1 is inhibited by anti-oncostatin M receptor beta monoclonal antibody KPL-716","volume":"100","author":"Richards","year":"2020","journal-title":"Acta Derm Venereol"},{"key":"10.1016\/j.ad.2023.06.007_bib0920","doi-asserted-by":"crossref","first-page":"738907","DOI":"10.3389\/fimmu.2021.738907","article-title":"Efficacy and safety of dupilumab in moderate-to-severe bullous pemphigoid","volume":"12","author":"Zhang","year":"2021","journal-title":"Front Immunol"},{"key":"10.1016\/j.ad.2023.06.007_bib0925","article-title":"Anogenital pruritus \u2013 an overview","volume":"10","author":"Swamiappan","year":"2016","journal-title":"J Clin Diagn Res"},{"key":"10.1016\/j.ad.2023.06.007_bib0930","doi-asserted-by":"crossref","first-page":"846","DOI":"10.1111\/codi.14997","article-title":"Intradermal 1% methylene blue injection for intractable idiopathic pruritus ani \u2013 a video vignette","volume":"22","author":"Samalavicius","year":"2020","journal-title":"Colorect Dis"},{"key":"10.1016\/j.ad.2023.06.007_bib0935","doi-asserted-by":"crossref","first-page":"3790","DOI":"10.1038\/s41467-020-17582-x","article-title":"Molecular mechanisms underlying menthol binding and activation of TRPM8 ion channel","volume":"11","author":"Xu","year":"2020","journal-title":"Nat Commun"},{"key":"10.1016\/j.ad.2023.06.007_bib0940","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1016\/j.jaad.2016.10.030","article-title":"Topical ketamine\u2013amitriptyline\u2013lidocaine for chronic pruritus: a retrospective study assessing efficacy and tolerability","volume":"76","author":"Lee","year":"2017","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.ad.2023.06.007_bib0945","doi-asserted-by":"crossref","first-page":"858","DOI":"10.1111\/j.1365-4632.2010.04537.x","article-title":"Systematic review of topical capsaicin in the treatment of pruritus","volume":"49","author":"Gooding","year":"2010","journal-title":"Int J Dermatol"},{"issue":"Suppl. 100","key":"10.1016\/j.ad.2023.06.007_bib0950","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/all.12531","article-title":"Update on rupatadine in the management of allergic disorders","volume":"70","author":"Mullol","year":"2015","journal-title":"Allergy"},{"key":"10.1016\/j.ad.2023.06.007_bib0955","doi-asserted-by":"crossref","first-page":"341","DOI":"10.2165\/00003495-200565030-00004","article-title":"Second-generation antihistamines: actions and efficacy in the management of allergic disorders","volume":"65","author":"Golightly","year":"2005","journal-title":"Drugs"},{"key":"10.1016\/j.ad.2023.06.007_bib0960","doi-asserted-by":"crossref","first-page":"1544","DOI":"10.1046\/j.1365-2222.2003.01701.x","article-title":"Ebastine inhibits T cell migration, production of Th2-type cytokines and proinflammatory cytokines","volume":"33","author":"Nori","year":"2003","journal-title":"Clin Exp Allergy"},{"key":"10.1016\/j.ad.2023.06.007_bib0965","doi-asserted-by":"crossref","first-page":"333","DOI":"10.3389\/fmed.2018.00333","article-title":"The antipruritic effect of phototherapy","volume":"5","author":"Legat","year":"2018","journal-title":"Front Med (Lausanne)"},{"key":"10.1016\/j.ad.2023.06.007_bib0970","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/j.det.2019.08.008","article-title":"Phototherapy for itch","volume":"38","author":"Zhong","year":"2020","journal-title":"Dermatol Clin"},{"key":"10.1016\/j.ad.2023.06.007_bib0975","doi-asserted-by":"crossref","first-page":"e2210339","DOI":"10.1001\/jamanetworkopen.2022.10339","article-title":"Efficacy and safety of difelikefalin in Japanese patients with moderate to severe pruritus receiving hemodialysis: a randomized clinical trial","volume":"5","author":"Narita","year":"2022","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.ad.2023.06.007_bib0980","doi-asserted-by":"crossref","first-page":"9","DOI":"10.2147\/IJNRD.S145720","article-title":"Post-marketing surveillance study of the safety and efficacy of nalfurafine hydrochloride (Remitch\u00ae capsules 2.5\u03bcg) in 3762 hemodialysis patients with intractable pruritus","volume":"11","author":"Kozono","year":"2018","journal-title":"Int J Nephrol Renovasc Dis"},{"key":"10.1016\/j.ad.2023.06.007_bib0985","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1016\/S0190-9622(08)81120-6","article-title":"Nalmefene and pruritus","volume":"23","author":"Harrison","year":"1990","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.ad.2023.06.007_bib0990","first-page":"222","article-title":"Use of nalbuphine for treatment of neuraxial opioid-induced pruritus: a systematic review and meta-analysis","volume":"87","author":"Tubog","year":"2019","journal-title":"AANA J"},{"key":"10.1016\/j.ad.2023.06.007_bib0995","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1016\/j.jaad.2005.12.010","article-title":"Butorphanol for treatment of intractable pruritus","volume":"54","author":"Dawn","year":"2006","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.ad.2023.06.007_bib1000","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1200\/JOP.18.00797","article-title":"Naloxone and maintenance naltrexone as novel and effective therapies for immunotherapy-induced pruritus: a case report and brief literature review","volume":"15","author":"Singh","year":"2019","journal-title":"J Oncol Pract"},{"key":"10.1016\/j.ad.2023.06.007_bib1005","first-page":"533","article-title":"Efficacy and safety of naltrexone, an oral opiate receptor antagonist, in the treatment of pruritus in internal and dermatological diseases","volume":"41","author":"Metze","year":"1999","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.ad.2023.06.007_bib1010","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1111\/jdv.17816","article-title":"Efficacy and safety of oral nalbuphine extended release in prurigo nodularis: results of a phase 2 randomized controlled trial with an open-label extension phase","volume":"36","author":"Weisshaar","year":"2022","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.ad.2023.06.007_bib1015","doi-asserted-by":"crossref","first-page":"1068","DOI":"10.1016\/j.jaad.2017.08.025","article-title":"Use of oral antidepressants in patients with chronic pruritus: a systematic review","volume":"77","author":"Kouwenhoven","year":"2017","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.ad.2023.06.007_bib1020","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1007\/s13555-016-0122-9","article-title":"A review of the efficacy of thalidomide and lenalidomide in the treatment of refractory prurigo nodularis","volume":"6","author":"Lim","year":"2016","journal-title":"Dermatol Ther (Heidelb)"},{"key":"10.1016\/j.ad.2023.06.007_bib1025","doi-asserted-by":"crossref","first-page":"e154","DOI":"10.1002\/hsr2.154","article-title":"Evaluation of apremilast in chronic pruritus of unknown origin: a proof-of-concept, phase 2a, open-label, single-arm clinical trial","volume":"3","author":"Clark","year":"2020","journal-title":"Health Sci Rep"},{"key":"10.1016\/j.ad.2023.06.007_bib1030","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1016\/j.jaad.2021.10.027","article-title":"Difamilast ointment in adult patients with atopic dermatitis: a phase 3 randomized, double-blind, vehicle-controlled trial","volume":"86","author":"Saeki","year":"2022","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.ad.2023.06.007_bib1035","doi-asserted-by":"crossref","first-page":"e765","DOI":"10.1111\/jdv.18275","article-title":"Rapid clearing of refractory nummular dermatitis with oral roflumilast therapy","volume":"36","author":"Gyldenl\u00f8ve","year":"2022","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.ad.2023.06.007_bib1040","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1111\/bjd.21744","article-title":"Considerable improvement in hidradenitis suppurativa with oral roflumilast therapy","volume":"187","author":"Ring","year":"2022","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.ad.2023.06.007_bib1045","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1056\/NEJMoa2000073","article-title":"Trial of roflumilast cream for chronic plaque psoriasis","volume":"383","author":"Lebwohl","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ad.2023.06.007_bib1050","doi-asserted-by":"crossref","DOI":"10.1016\/j.jaad.2016.02.1237","article-title":"Gabapentin and pregabalin for the treatment of chronic pruritus","volume":"75","author":"Matsuda","year":"2016","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.ad.2023.06.007_bib1055","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/S0304-3959(03)00173-8","article-title":"Pregabalin and gabapentin reduce release of substance P and CGRP from rat spinal tissues only after inflammation or activation of protein kinase C","volume":"105","author":"Fehrenbacher","year":"2003","journal-title":"Pain"},{"key":"10.1016\/j.ad.2023.06.007_bib1060","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1111\/dth.12026","article-title":"Practical guidelines for the use of steroid-sparing agents in the treatment of chronic pruritus","volume":"26","author":"Cotes","year":"2013","journal-title":"Dermatol Ther"},{"key":"10.1016\/j.ad.2023.06.007_bib1065","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.ad.2017.05.005","article-title":"Practical management of immunosuppressants in dermatology","volume":"109","author":"Leis-Dosil","year":"2018","journal-title":"Actas Dermosifiliogr (Engl Ed)"},{"key":"10.1016\/j.ad.2023.06.007_bib1070","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.3390\/ph15081022","article-title":"Treatment options for troublesome itch","volume":"15","author":"Toyama","year":"2022","journal-title":"Pharmaceuticals (Basel)"},{"key":"10.1016\/j.ad.2023.06.007_bib1075","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1111\/dth.12032","article-title":"The effects of treatment on itch in atopic dermatitis","volume":"26","author":"Yarbrough","year":"2013","journal-title":"Dermatol Ther"},{"key":"10.1016\/j.ad.2023.06.007_bib1080","doi-asserted-by":"crossref","DOI":"10.2340\/00015555-3360","article-title":"Methotrexate in the treatment of chronic itch in the geriatric population","volume":"100","author":"Kursewicz","year":"2020","journal-title":"Acta Derm Venereol"},{"key":"10.1016\/j.ad.2023.06.007_bib1085","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1111\/jdv.14646","article-title":"Treatment of prurigo with methotrexate: a multicentre retrospective study of 39 cases","volume":"32","author":"Klejtman","year":"2018","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.ad.2023.06.007_bib1090","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1016\/j.jaad.2015.05.025","article-title":"Azathioprine treatment of intractable pruritus: a retrospective review","volume":"73","author":"Maley","year":"2015","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.ad.2023.06.007_bib1095","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1080\/09546634.2019.1642996","article-title":"Mycophenolate mofetil and atopic dermatitis: systematic review and meta-analysis","volume":"31","author":"Phan","year":"2020","journal-title":"J Dermatolog Treat"},{"key":"10.1016\/j.ad.2023.06.007_bib1100","doi-asserted-by":"crossref","first-page":"4790810","DOI":"10.1155\/2017\/4790810","article-title":"Aprepitant for the treatment of chronic refractory pruritus","volume":"2017","author":"He","year":"2017","journal-title":"Biomed Res Int"},{"key":"10.1016\/j.ad.2023.06.007_bib1105","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1016\/j.det.2018.02.011","article-title":"Pruritus in cutaneous T-cell lymphoma and its management","volume":"36","author":"Serrano","year":"2018","journal-title":"Dermatol Clin"},{"key":"10.1016\/j.ad.2023.06.007_bib1110","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1016\/j.lungcan.2017.04.020","article-title":"Aprepitant for refractory nivolumab-induced pruritus","volume":"109","author":"Ito","year":"2017","journal-title":"Lung Cancer"},{"key":"10.1016\/j.ad.2023.06.007_bib1115","doi-asserted-by":"crossref","first-page":"e14698","DOI":"10.1111\/dth.14698","article-title":"Benefits and harms of NK1 R antagonists in pruritus: a systematic review and meta-analysis","volume":"34","author":"Yang","year":"2021","journal-title":"Dermatol Ther"},{"key":"10.1016\/j.ad.2023.06.007_bib1120","doi-asserted-by":"crossref","first-page":"e338","DOI":"10.1111\/jdv.17090","article-title":"Neurokinin-1 receptor antagonist tradipitant has mixed effects on itch in atopic dermatitis: results from EPIONE, a randomized clinical trial","volume":"35","author":"Welsh","year":"2021","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.ad.2023.06.007_bib1125","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1016\/j.jid.2015.12.037","article-title":"Intrathecal minocycline suppresses itch-related behavior and improves dermatitis in a mouse model of atopic dermatitis","volume":"136","author":"Torigoe","year":"2016","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.ad.2023.06.007_bib1130","doi-asserted-by":"crossref","first-page":"201","DOI":"10.2174\/1573396316666200923161330","article-title":"Pityriasis rosea: an updated review","volume":"17","author":"Leung","year":"2021","journal-title":"Curr Pediatr Rev"},{"key":"10.1016\/j.ad.2023.06.007_bib1135","doi-asserted-by":"crossref","first-page":"2039","DOI":"10.1111\/jdv.15813","article-title":"A systematic review of treatments for pityriasis lichenoides","volume":"33","author":"Bellinato","year":"2019","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.ad.2023.06.007_bib1140","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1016\/j.jpainsymman.2011.11.007","article-title":"The role of ondansetron in the management of cholestatic or uremic pruritus \u2013 a systematic review","volume":"44","author":"To","year":"2012","journal-title":"J Pain Sympt Manage"}],"container-title":["Actas Dermo-Sifiliogr\u00e1ficas"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S000173102300474X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S000173102300474X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,11]],"date-time":"2025-09-11T01:14:42Z","timestamp":1757553282000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S000173102300474X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,7]]},"references-count":114,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2023,7]]}},"alternative-id":["S000173102300474X"],"URL":"https:\/\/doi.org\/10.1016\/j.ad.2023.06.007","relation":{},"ISSN":["0001-7310"],"issn-type":[{"value":"0001-7310","type":"print"}],"subject":[],"published":{"date-parts":[[2023,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"[Translated article] Pruritus in Dermatology: Part 2\u2014Diseases and Their Treatment","name":"articletitle","label":"Article Title"},{"value":"Actas Dermo-Sifiliogr\u00e1ficas","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ad.2023.06.007","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"https:\/\/doi.org\/10.1016\/j.ad.2023.03.004","name":"associatedlink","label":"CrossRef DOI link to the associated document"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 AEDV. Published by Elsevier Espa\u00f1a, S.L.U.","name":"copyright","label":"Copyright"}]}}